COMPASS-TNBC
COMPASS-TNBC (Choice Of the Most Active Strategies for Short term recurring triple negative breast cancer)
Is a phase I/II clinical trial designed to evaluate the efficacy and provide access to innovative therapies for patients with early-relapsed metastatic triple-negative breast cancer.
Academic Program
Developed at Gustave Roussy
This comprehensive academic program, developed in collaboration between Gustave Roussy and the industry, aims to rapidly discover an effective treatment for short-term recurrent metastatic triple-negative breast cancer. The program also incorporates a translational research component to better understand the disease’s distinct characteristics, mechanisms of action, and resistance to treatments.
SHORT-TERM RECURRENT TRIPLE-NEGATIVE BREAST CANCER
Triple-negative breast cancer refers to breast tumours that do not express hormone receptors and HER2. When diagnosed at an early stage, i.e. confined to the breast and nearby lymph nodes, patients with this type of cancer are offered a multimodal treatment approach that includes chemotherapy, surgery, radiotherapy and sometimes adjuvant therapy. With this combined strategy, can successfully cure a significant proportion of patients can be successfully cured and metastatic recurrence, i.e. the spread of tumour cells to organs outside the breast and lymph nodes, can be prevented.
While more than half of patients with triple-negative breast cancer respond well to conventional chemotherapy, the other half may develop resistance and experience a relapse, which can occur early after the completion of curative treatment.
To date, there is no treatment that can cure metastatic breast cancer. Significant therapeutic advances such as immunotherapy and chemotherapy-conjugated antibodies can help control the disease and prolong patients’ lives.
However, for patients with short-term recurrent triple-negative breast cancer, especially within the first year after completing curative treatment, there are limited effective therapeutic strategies. These tumours proliferate extraordinarily rapidly and appear to have intrinsic resistance mechanisms to treatment.